AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21751165
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no lithium treatment)
Trial: 16424409
Drug: Salmeterol, 42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol, 42 mug bid via metered-dose inhaler (MDI)
Trial: 16424409
Drug: Placebo bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid via metered-dose inhaler (MDI)
Trial: 15274385
Drug: Epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg/m2 plus docetaxel 90 mg/m2 every 3 weeks with prophylactic G‐CSF
Trial: 14517197
Drug: Diltiazem HCl
RxNorm normalized name: DILTIAZEM HCL
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem HCl ER tablets administered in the evening (360 mg single-dose and multiple-dose for 7 days)
Trial: 14517197
Drug: Diltiazem HCl
RxNorm normalized name: DILTIAZEM HCL
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem HCl ER tablets administered in the evening (360 mg once daily for 7 days)
Trial: 14517197
Drug: Diltiazem HCl
RxNorm normalized name: DILTIAZEM HCL
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem HCl ER tablets administered in the evening
Trial: 10200003
Drug: LEV 0.1
RxNorm normalized name: NuLev 0.125mg Chewable Melt Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 0.1 mg
Trial: 10200003
Drug: LEV 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 0.2 mg
Trial: 10200003
Drug: LEV 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 0.4 mg
Trial: 2156368
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with unprocessed wheat bran (30 g of dietary fiber)
Trial: 702130
Drug: Dextroamphetamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (0.5 mg/kg)
Trial: 1783082
Drug: Placebo elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo elixir
Trial: 25805187
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg + low-dose metformin (1000 mg)
Trial: 25805187
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin (2000 mg)
Trial: 25805187
Drug: Linagliptin +
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin + low-dose metformin (1000 mg)
Trial: 23856559
Drug: Dronabinol (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (maximum dose 28 mg per day, titrated against bodyweight and adverse effects)
Trial: 17470688
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy with a platinum-based doublet followed by a single agent.
Trial: 17470688
Drug: Sequential single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential single agents.
Trial: 17470688
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy strategy.
Trial: 17470688
Drug: Consolidation/maintenance chemotherapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation/maintenance chemotherapy.
Trial: 15104322
Drug: Thermoluminescent dosemeters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermoluminescent dosemeters (TLD) used to assess operators' extremity doses during procedures
Trial: 15104322
Drug: Preliminary occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preliminary occupational dose constraint value calculated from cardiologists' annual effective dose
Trial: 29885911
Drug: Intra-articular Botulinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular Botulinum toxin injections (30 units)
Trial: 19065894
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg/d) and Bailing Capsule (2.0 g, twice a day)
Trial: 19065894
Drug: Bailing Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bailing Capsule alone
Trial: 19065894
Drug: Immunosuppressive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive agents (control)
Trial: 16648320
Drug: 10,000-lux light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000-lux light treatment and placebo capsule
Trial: 16648320
Drug: 100-lux light
RxNorm normalized name: mineral oil, light
DrugBank: Light mineral oil (DB11579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-lux light treatment (placebo light) and fluoxetine, 20 mg/day
Trial: 10994615
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of serum pepsinogen I assay and H. pylori IgG serology
Trial: 9011452
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) treatment (13-15 mg/kg/day for >3 months)
Trial: 9011452
Drug: UDCA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA treatment (38+/‐8 months)
Trial: 2869470
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg clorazepate dipotassium
Trial: 29570501
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% at injection speed of 12 mL/h
Trial: 29570501
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% at injection speed of 60 mL/h
Trial: 29570501
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% at injection speed of 300 mL/h
Trial: 29570501
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% at injection speed of 600 mL/h
Trial: 29570501
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% at injection speed of 1800 mL/h
Trial: 26697890
Drug: Mildronate injection
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mildronate injection 250 mg
Trial: 26697890
Drug: Mildronate injection
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mildronate injection 500 mg
Trial: 26697890
Drug: Mildronate injection
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mildronate injection 750 mg
Trial: 26697890
Drug: Multiple-dose mildronate
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose mildronate administration
Trial: 22658758
Drug: Normal baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal baseline testosterone (≥10 nmol/l)
Trial: 19369866
Drug: Oral glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glycerol (GLY)
Trial: 19369866
Drug: Dexamethasone (DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXM) and Oral glycerol (GLY)
Trial: 17683328
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of hydroxyzine (Atarax) 24 h preoperatively and 3.7 mg/kg hydroxyzine orally on the operation day
Trial: 17683328
Drug: 3.7 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.7 mg/kg hydroxyzine orally only on the operation day
Trial: 12196363
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus chemotherapy (TAM-CT group)
Trial: 7649959
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at doses of 0.3, 0.6, 0.9 mg/kg
Trial: 326385
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone and polychemotherapy (oophorectomy plus modified five-drug 'Cooper' combination)
Trial: 326385
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone and polychemotherapy (diethylstilbestrol and cytostatic therapy)
Trial: 326385
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus progesterone
Trial: 26505681
Drug: XELIRI/FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELIRI/FOLFIRI plus simvastatin (40 mg)
Trial: 17827829
Drug: Telmisartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (20 mg/day)
Trial: 17827829
Drug: Valsartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (40 mg/day)
Trial: 15214905
Drug: Two-compound product
RxNorm normalized name: Ceo-Two Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound product (calcipotriol/betamethasone dipropionate) once daily for 8 weeks followed by calcipotriol ointment once daily for 4 weeks
Trial: 15214905
Drug: Two-compound product
RxNorm normalized name: Ceo-Two Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound product (calcipotriol/betamethasone dipropionate) once daily for 4 weeks followed by calcipotriol ointment once daily on weekdays and the two-compound product once daily at weekends
Trial: 15214905
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment twice daily for 12 weeks
Trial: 11816704
Drug: Mesoglycan 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally for 20 weeks
Trial: 9522105
Drug: Cefaclor 25
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 25 mg/kg BID
Trial: 9522105
Drug: Amoxicillin-clavulanate 15
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate 15 mg/kg TID
Trial: 9522105
Drug: Erythromycin 15
RxNorm normalized name: erythromycin 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 15 mg/kg TID
Trial: 2508608
Drug: Deprenyl 10
RxNorm normalized name: (11C)L-deprenyl-D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl 10 mg/d
Trial: 2508608
Drug: Deprenyl 10
RxNorm normalized name: (11C)L-deprenyl-D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl 10 mg/d and Tocopherol (vitamin E) 2000 IU/d
Trial: 324773
Drug: Phenylbutazone (300‐400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (300‐400 mg daily)
Trial: 27459586
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor inhibitor monotherapy
Trial: 27459586
Drug: Castration plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Castration plus an androgen receptor inhibitor
Trial: 10338176
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg lidocaine
Trial: 24595146
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg lidocaine
Trial: 20117379
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin + omega-3 fatty acids (4 capsules daily)
Trial: 17288699
Drug: Clarithromycin extended-release
RxNorm normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin extended-release (ER) 1000 mg once daily for 5 days
Trial: 15801995
Drug: Clarithromycin immediate-release
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin immediate-release (IR) 500 mg twice daily for 7 days
Trial: 11929392
Drug: Cisapride, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 10 mg q.d.s.
Trial: 2028396
Drug: Postoperative telecobalt
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative telecobalt therapy
Trial: 2028396
Drug: Postoperative electron
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative electron therapy
Trial: 26652921
Drug: Buccal translation
RxNorm normalized name: CONNECTOR,ENFIT TRANSITIONAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal translation of maxillary first premolar with 50 g of force
Trial: 26652921
Drug: Buccal translation
RxNorm normalized name: CONNECTOR,ENFIT TRANSITIONAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal translation intervention
Trial: 20510026
Drug: Conventional systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional systemic therapy and management of airway (Control)
Trial: 16383040
Drug: 1 g/100
RxNorm normalized name: Cefotan, 1 g/100 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/100 cm2 Dermlin topical application
Trial: 16383040
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of silver sulfadiazine (SD - Ag) cream
Trial: 16383040
Drug: 1 g/100
RxNorm normalized name: Cefotan, 1 g/100 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/100 cm2 Dermlin treatment for diabetic foot ulcers
Trial: 16383040
Drug: Cell culture
RxNorm normalized name: Rabies - IM Diploid cell culture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell culture with 20 g/L Dermlin
Trial: 16383040
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of silver sulfadiazine (SD - Ag) cream in animal test
Trial: 12031758
Drug: CR oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR oxycodone 10 mg
Trial: 10082174
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release capsule (300 mg sodium valproate)
Trial: 10082174
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (300 mg sodium valproate)
Trial: 10082174
Drug: Enteric-coated tablet
RxNorm normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated tablet (300 mg sodium valproate)
Trial: 7788460
Drug: Social milieu
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social milieu treatment
Trial: 20217203
Drug: Rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (40 mg loading dose administered 24 h before PCI)
Trial: 16162709
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (hyperpnea training + endurance training)
Trial: 12095312
Drug: 4-Phenylbutyrate (Buphenyl)
RxNorm normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-Phenylbutyrate (Buphenyl) at doses of 20, 30, or 40 g divided t.i.d. for 1 week
Trial: 10726022
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin 50 mg
Trial: 38175
Drug: Three drugs
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three drugs in widespread clinical use for Crohn's disease (specific drugs not mentioned)
Trial: 38175
Drug: Prednisone (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (adjusted dose based on illness severity)
Trial: 27775407
Drug: Ingroup members'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingroup members' emotional expressions (e.g., fearful, happy, neutral)
Trial: 24780615
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) 700‐1000 mg iron (according to calculated iron deficit on postoperative day 2)
Trial: 24780615
Drug: Ferrous glycine
RxNorm normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous glycine sulphate (FS) 100 mg iron daily from day 7 onwards
Trial: 10528328
Drug: New dopaminergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New dopaminergic agonists (carbergolin, pramipexol, ropinirol)
Trial: 10528328
Drug: Catechol-O-methyl-transferase (COMT)
RxNorm normalized name: 2,3 di-o-methyl-d-glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catechol-O-methyl-transferase (COMT) inhibitors (entacapone, tolcapone)
Trial: 1702663
Drug: 300 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms of selenium in high Se malt cakes daily for one year
Trial: 1702663
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of malt cakes daily for one year
Trial: 30160651
Drug: Dopamine receptor
RxNorm normalized name: Dopamine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine receptor antagonist
Trial: 26739331
Drug: Sequential learning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential learning using a transparent shoebox for psychomotor skills followed by a box trainer for knot tying.
Trial: 25299806
Drug: Modified Network
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Network for Improvement of Addiction Treatment (NIATx) change team approach
Trial: 22341703
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review by a pharmacist
Trial: 19811776
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg d‐cycloserine
Trial: 15642799
Drug: pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone (30 mg/day)
Trial: 15642799
Drug: metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (850 mg, three times a day)
Trial: 8039988
Drug: Rectal temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal temperature measurements
Trial: 23090093
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Limaprost + NSAIDs)
Trial: 22158670
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamin C 120 mg, vitamin E 30 mg, beta-carotene 6 mg, selenium 100 μg, zinc 20 mg)
Trial: 7824599
Drug: 40% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% sucrose solution
Trial: 2969799
Drug: urapidil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil (120 mg/day initially, increased to 180 mg/day if necessary)
Trial: 2969799
Drug: methyldopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyldopa (100 mg/day initially, increased to 1500 mg/day if necessary)
Trial: 21382484
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine with a 4-week interval between doses (MMRV-4W)
Trial: 21382484
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine with a 12-month interval between doses (MMRV-12M)
Trial: 21382484
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine with a 4-week interval between doses (MMR)
Trial: 16722837
Drug: Antidiabetic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic medication
Trial: 12057040
Drug: Gemcitabine 1200
RxNorm normalized name: gemcitabine 1200 MG in 120 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1200 mg/m2 over 30 minutes on days 1 and 8 every 21 days plus trastuzumab 4 mg/kg over 90 minutes, followed by 2 mg/kg weekly.
Trial: 12057040
Drug: Gemcitabine/trastuzumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/trastuzumab treatment
Trial: 10460066
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg l-menthol capsule
Trial: 10460066
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg menthol in mint candy or mint tea
Trial: 1971650
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g CAZ administered 140 min prior to puncture (group I)
Trial: 1971650
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 2 g CAZ one day before and 2 g 2 h prior to puncture (group II)
Trial: 1971650
Drug: CAZ concentrations
RxNorm normalized name: CAZ
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAZ concentrations at 4 h after infusion
Trial: 1971650
Drug: CAZ concentrations
RxNorm normalized name: CAZ
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAZ concentrations at 6 h after infusion